Detection of AmpC beta-Lactamases in Gram-negative Bacteria Isolated from Urine
Authors:
L. Černohorská; T. Andrysík
Authors‘ workplace:
Mikrobiologický ústav Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice u sv. Anny v Brně
Published in:
Epidemiol. Mikrobiol. Imunol. 57, 2008, č. 4, s. 141-146
Overview
AmpC beta-lactamases, enzymes produced by a range of Gram-negative bacteria and able to hydrolyse penicillins, monobactams, cephalosporins and cephamycins, are not inhibited by beta-lactamase inhibitors. They are spread via plasmids and pose a huge epidemiological and diagnostic problem.
The production of AmpC ß-lactamases was tested in various Gram-negative bacteria. Of strains isolated from urine of patients diagnosed with urinary tract infection, we selected those that were resistant to third generation cephalosporins and did not produce extended-spectrum beta-lactamases (ESBL). The production of inducible AmpC was assayed by modified DDST (double disk synergy test) and that of constitutive AmpC was tested on agar containing oxacillin as an AmpC inhibitor. All constitutive AmpC producers were also tested for susceptibility to amikacin, piperacillin/tazobactam, cefoperazon/sulbactam, imipenem, meropenem and colistin by the disk diffusion method on MH-agar.
Altoghether 119 strains (68 strains of Klebsiella pneumoniae, 20 strains of Escherichia coli and 12 strains of Enterobacter aerogenes) were tested. We detected 38 constitutive AmpC producers, including primarily K. pneumoniae (17 strains), E. coli (10 strains) and E. aerogenes (4 strains). Thirty-two strains were inducible AmpC producers (21 K. pneumoniae strains, 6 Morganella morganii strains and 3 E. aerogenes strains). Two K. pneumoniae strains were ESBL/AmpC coproducers. The constitutive AmpC producers showed relatively good susceptibility to cefepim (84.2 %) and carbapenems.
Key words:
AmpC – ESBL – Gram-negative bacteria – urinary tract infection.
Sources
1. Alvarez, M., Tran, J. H., Chow, N. et al. Epidemiology of conjugative plasmid-mediated AmpC ß-lactamases in the United States. Antimicrob Agents Chemother, 2004, 48, 533-537.
2. Ambler, R. P. The structure of ß-lactamases. Phil Trans R Soc Lond Biol, 1980, B 289, 321-331.
3. Bradford, P. Extended-spectrum ß-lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clin Microbiol Rev, 2001, 14, 933-951.
4. Bush, K., Jacoby, G. A., Medeiros, A. A. A functional classification scheme for ß-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother, 1995, 39, 1211-1233.
5. Courdon, P. E., Moland, E. S., Thomson, K. S. Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis Isolates at a Veterans Medical Center. J Clin Microbiol, 2000, 38, 1791-1796.
6. Dunne, W. M., Hardin, D. J. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol, 2005, 43, 5945-5949.
7. Fortineau, N., Poirel, L., Nordmann, P. Plasmid-mediated and inducible cephalosporinase DHA-2 from Klebsiella pneumoniae. J Antimicrob Chemother, 2001, 47, 207-210.
8. Giamarellos-Bourboulis, E. J., Papadimitriou, E., Galanakis, N. et al. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents, 2006, 27, 476-481.
9. Hanson, N. D. AmpC ß-lactamases: what do we need to know for the future? J Antimicrob Chemother, 2003, 52, 2-4.
10. Hrabák, J. Klinicky významné ß-laktamázy gramnegativních bakterií: AmpC. Epidemiol Mikrobiol Imununol, 2007, 56, 155-165.
11. Hrabák, J., Vaniš, V., Bergerová, T. et al. Průkaz ß-laktamáz širokého spektra (ESBL) a typu AmpC u enterobakterií. Zprávy CEM (SZÚ Praha), 2007, 16, 31-36.
12. Chromá, M., Kolář, M., Sauer, P. et al. Molekulárno-biologická analýza ESBL-pozitívnych izolátov Klebsiella pneumoniae od pacientov v intenzívnej starostlivosti. Klinická mikrobiologie a infekční lékařství, 2007, 13, 206-211.
13. Jacoby, G. A, Walsh, K. E., Walker, V. Identification of extended-spectrum, AmpC, and carbapenem-hydrolyzing ß-lactamases in Escherichia coli and Klebsiella pneumoniae by disk tests. J Clin Microbiol, 2006, 44, 1971-1976.
14. Kolář, M. Klinický význam širokospektrých ß-laktamáz a zkušenosti s jejich identifikací v mikrobiologické praxi. Klinická mikrobiologie a infekční lékařství, 2007, 13, 195-205.
15. Kolář, M. Vývoj bakteriální rezistence a nová antimikrobní léčiva. Interní med, 2007, 5, 213-216.
16. Kolář, M., Látal, T., Čermák, P. et al. Prevalence of extended-spectrum ß-lactamase-positive Klebsiella pneumoniae isolates in the Czech Republic. Int J Antimicrob Agents, 2006, 28, 49-53.
17. Kolář, M., Urbánek, K., Látal, M. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents, 2001, 17, 357-363.
18. Kolář, M., Urbánek, K., Lochmannová, J. Výchozí zdroje racionální antibiotické léčby bakteriálních infekcí. Prakt Lékáren, 2006, 1, 20-23.
19. Laxminarayan, R. Antibiotic resistance: The unfolding crisis. In: Laxminarayan, R., Malani, A., Howard, D. et al. Extending the cure - Policy responses to the growing threat of antibiotic resistance. Washington D.C., Resources for the Future, 2007, 25-34. ISBN 978-1-933115-57-3.
20. Padilla, E., Alonso, D., Doménech-Sánchez, A. et al. Effect of porins and plasmid-mediated AmpC ß-lactamases on the efficacy of ß-lactams in rat pneumonia caused by Klebsiella pneumoniae. Antimicrob Agents Chemother, 2006, 50, 2258-2260.
21. Philippon, A., Arlet, G., Jacoby, G. A. Plasmid-determined AmpC-type ß-lactamases. Antimicrob Agents Chemother, 2002, 46, 1-11.
22. Rijavec, M., Budič, M., Mrak, P. et al. Prevalence of COLE1-like plasmids and Colicin K production among uropathogenic Escherichia coli strains and quantification of inhibitory activity of Colicin K. Appl Environ Microbiol, 2007, 73, 1029-1032.
23. Song, W., Moland, E. S., Hanson, N. D. et al. Failure of cefepime therapy in treatment of Klebsiella pneumoniae Bacteremia. J Clin Microbiol, 43, 2005, 43, 4891-4894.
24. Taneja, N., Rao, P., Arora, J. et al. Occurrence of ESBL & Amp-C ß-lactamases & susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res, 2008, 127, 85-88.
25. Thomson, K. S. Controversies about Extended-Spectrum and AmpC beta-lactamases. Emerg Inf Dis, 2001, 7, 333-336.
26. Trautner, B. W., Hull, R. A., Darouiche, R.O. Colicins prevent colonization of urinary catheters. J Antimicrob Chemoter, 2005, 56, 413-415.
27. Urbánek, K., Kolář, M., Lovečková, Y. et al. Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains. J Clin Pharm Therapeut, 2007, 32, 403-408.
28. Urbášková, P. Rezistence bakterií k antibiotikům. Vybrané metody, Trios, 1998.
Labels
Hygiene and epidemiology Medical virology Clinical microbiologyArticle was published in
Epidemiology, Microbiology, Immunology
2008 Issue 4
Most read in this issue
- Carbapenem Resistance in Enterobacteria
- ecal Calprotectin Levels in Patients with Idiopathic Inflammatory Bowel Disease – Comparison of Two Commercial Tests
- Detection of AmpC beta-Lactamases in Gram-negative Bacteria Isolated from Urine
- Ilya Ilich Metchnikov and Paul Ehrlich: 1908 Nobel Prize Winners for their Research on Immunity.